Novartis Confirms Benefits of Fabhalta in Rare Kidney Disease
Novartis has confirmed the benefits of its drug Fabhalta in treating IgA nephropathy, a rare kidney disease.
The company has high hopes for Fabhalta, with potential earnings of $3 billion. Fabhalta has already received accelerated approval for IgAN and FDA clearance for paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
- Fabhalta brought in $120 million in the second quarter.
- The company plans to submit Fabhalta for at least three more new indications over the next few years.
The latest research comes as Novartis and competitors focus on IgAN.
Author's summary: Novartis confirms Fabhalta's benefits in rare kidney disease.